Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8VUX3)

Drug Name
15-deoxy-Delta(12, 14)-prostaglandin J(2) Drug Info
Synonyms
15d-PGJ2; 15-Deoxy-PGJ2; 15-Deoxy-delta-12,14-prostaglandin J2; 15-deoxy-delta12,14-prostaglandin J2; delta12,14-PGJ 2; UNII-ALI977775J; 87893-55-8; CHEMBL482477; CHEBI:34159; (5Z,12E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid; ALI977775J; delta-12,14-15-Deoxy-PGJ2; 15-Deoxy-delta12,14-prostaglandin; 15-deoxy-Delta(12,14)-prostaglandin J2; Prostaglandin J2, 15-Deoxy-Delta12,14; 15-Deoxy-delta 12, 14-Prostaglandin J2
Cross-matching ID
PubChem CID
5311211
ChEBI ID
CHEMBL482477
CAS Number
CAS 87893-55-8
TTD Drug ID
D01PGU

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.40 0.00e+0 44/46 (95.65%) PSMC2;PSMB7;PSMC6;...
DNA replication 2.06 0.00e+0 34/36 (94.44%) PCNA;RFC4;POLD3;...
Spinocerebellar ataxia 2.06 0.00e+0 128/143 (89.51%) PSMC2;PSMB7;PSMC6;...
Amyotrophic lateral sclerosis 2.00 3.48e-3 267/364 (73.35%) GPX2;PFN2;RAE1;...
Glutathione metabolism 1.91 4.18e-3 43/57 (75.44%) GCLM;GPX2;ODC1;...
Huntington disease 1.90 3.48e-3 233/306 (76.14%) GPX2;NDUFA4;CASP3;...
Ferroptosis 1.88 3.98e-3 36/41 (87.8%) HMOX1;SLC7A11;GCLM;...
Homologous recombination 1.86 4.35e-3 35/41 (85.37%) BARD1;POLD3;SEM1;...
Legionellosis 1.85 6.96e-3 51/57 (89.47%) HSPA1A;HSPA8;CD14;...
Spliceosome 1.82 9.75e-3 101/150 (67.33%) HSPA1A;HSPA8;PRPF4;...
Parkinson disease 1.81 1.01e-2 176/249 (70.68%) UCHL1;NDUFA4;CASP3;...
Cell cycle 1.79 1.39e-2 110/124 (88.71%) CDC25A;DBF4;CCNA2;...
Metabolism of xenobiotics by cytochrome P450 1.77 1.55e-2 49/77 (63.64%) AKR1C1;GSTM3;CYP1B1;...
Prion disease 1.77 1.49e-2 209/273 (76.56%) HSPA1A;HSPA8;NDUFA4;...
RNA transport 1.75 1.49e-2 128/186 (68.82%) RAE1;NUP50;RPP30;...
Folate biosynthesis 1.75 1.39e-2 23/26 (88.46%) AKR1C3;AKR1B10;CBR1;...
Mismatch repair 1.73 1.47e-2 22/23 (95.65%) PCNA;RFC4;POLD3;...
Ubiquinone and other terpenoid-quinone biosynthesis 1.69 2.13e-2 9/11 (81.82%) NQO1;COQ3
Oxidative phosphorylation 1.68 2.05e-2 93/133 (69.92%) NDUFA4;COX7B;NDUFB5;...
mRNA surveillance pathway 1.68 1.98e-2 71/98 (72.45%) PPP2R3C;PELO;ETF1;...
Porphyrin and chlorophyll metabolism 1.68 1.92e-2 23/43 (53.49%) HMOX1;FECH;HCCS;...
Nucleotide excision repair 1.66 2.15e-2 40/47 (85.11%) RAD23B;PCNA;RFC4;...
IL-17 signaling pathway 1.63 2.54e-2 84/94 (89.36%) S100A8;S100A9;LCN2;...
Steroid hormone biosynthesis 1.61 3.28e-2 43/61 (70.49%) AKR1C2;AKR1C1;AKR1C3;...
Pathways of neurodegeneration 1.60 3.68e-2 354/475 (74.53%) UCHL1;GPX2;NDUFA4;...
Alzheimer disease 1.59 3.96e-2 279/369 (75.61%) NDUFA4;CASP3;PSMC2;...
Ribosome biogenesis in eukaryotes 1.58 4.15e-2 52/108 (48.15%) RPP30;POP4;NXT2;...
Retinol metabolism -1.65 4.71e-2 41/68 (60.29%) UGT2A3;CYP1A2;RETSAT;...
Renin secretion -1.65 4.86e-2 61/69 (88.41%) AGT;GNAQ;EDN3;...
Viral myocarditis -1.68 3.79e-2 53/60 (88.33%) HLA-DRA;MYH6;HLA-C;...
Ras signaling pathway -1.68 3.85e-2 201/232 (86.64%) PLD1;RASGRP2;RAC3;...
PPAR signaling pathway -1.69 4.04e-2 66/74 (89.19%) AQP7;ACSBG1;CYP27A1;...
Platelet activation -1.69 3.92e-2 106/124 (85.48%) ITGA2;TLN2;ITGB1;...
Gastric acid secretion -1.70 3.99e-2 63/76 (82.89%) ADCY6;KCNJ1;CHRM3;...
Vascular smooth muscle contraction -1.71 3.70e-2 113/133 (84.96%) ACTG2;GNA13;PLA2G6;...
Adrenergic signaling in cardiomyocytes -1.73 2.97e-2 130/150 (86.67%) PPP1R1A;ACTC1;CAMK2A;...
cAMP signaling pathway -1.73 2.65e-2 188/216 (87.04%) GLI1;VIP;GABBR1;...
Rap1 signaling pathway -1.73 2.75e-2 184/210 (87.62%) VEGFB;LPAR3;PDGFB;...
Small cell lung cancer -1.74 2.96e-2 90/92 (97.83%) CDKN2B;PTGS2;ITGA2;...
Relaxin signaling pathway -1.74 3.00e-2 114/129 (88.37%) GNA15;NFKB1;MAPK3;...
Tight junction -1.76 3.03e-2 130/169 (76.92%) CD1A;MPDZ;CLDN6;...
Proteoglycans in cancer -1.80 2.31e-2 172/205 (83.9%) IHH;ITGB1;MAPK3;...
Leukocyte transendothelial migration -1.84 1.85e-2 90/114 (78.95%) ITGB1;CLDN8;MAPK11;...
Cell adhesion molecules -1.84 2.09e-2 118/148 (79.73%) HLA-C;ITGB1;NECTIN2;...
Regulation of lipolysis in adipocytes -1.89 1.47e-2 52/55 (94.55%) PTGS2;AQP7;PTGS1;...
Adherens junction -1.92 1.07e-2 63/71 (88.73%) TCF7L1;MAPK3;NECTIN2;...
Arrhythmogenic right ventricular cardiomyopathy -2.00 2.57e-3 70/77 (90.91%) SLC8A2;ITGA2;ITGB6;...
Hypertrophic cardiomyopathy -2.14 0.00e+0 81/90 (90%) TGFB2;ITGB8;MYBPC3;...
Dilated cardiomyopathy -2.23 0.00e+0 86/96 (89.58%) TGFB2;ITGB8;MYBPC3;...
Focal adhesion -2.24 0.00e+0 180/201 (89.55%) VEGFB;ITGA2;ITGB6;...
ECM-receptor interaction -2.25 0.00e+0 80/88 (90.91%) GP1BB;LAMB3;TNXB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 6.66uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.22uM - 2.22uM 48H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.22uM - 10uM 6H, 48H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H